Evotec SEEVO +1.11%64 Gross Margin % is -1.00% as of Mar. 2026. GuruFocus rates EVO with a GF Score™ of 64/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 938 Drug Manufacturers companies, Evotec SE ranks worse than 94.88% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Evotec SE's Gross Profit for the
three
months ended in Mar. 2026 was $-1.8 Mil. Evotec SE's Revenue for the
three
months ended in Mar. 2026 was $181.1 Mil. Therefore, Evotec SE's Gross Margin % for the quarter that ended in Mar. 2026 was -1.00%.
Warning Sign:
Evotec SE gross margin has been in long-term decline. The average rate of decline per year is -11.8%.
The historical rank and industry rank for Evotec SE's Gross Margin % or its related term are showing as below:
EVO'
s Gross Margin % Range Over the Past 10 Years
Min: 11.47 Med: 24.81 Max: 35.59
Current: 11.47
During the past 13 years, the highestGross Margin % of Evotec SE was 35.59%. The lowest was 11.47%. And the median was 24.81%.
EVO's Gross Margin % is ranked worse than 94.88% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs EVO: 11.47
Evotec SE had a gross margin of -1.00% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Evotec SE was -11.80% per year.
Evotec SE (NAS:EVO) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Evotec SE had a gross margin of -1.00% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Evotec SE Gross Margin % Related Terms
Evotec SE Gross Margin % Historical Data
* Premium members only.
The historical data trend for Evotec SE's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Evotec SE's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Evotec SE (EVO) has a Gross Margin % of -1.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Evotec SE and its competitors. Over the past decade, Evotec SE's Gross Margin % has ranged from 11.47 to 35.59. According to the industry distribution chart, Evotec SE ranks #890 out of 938 companies in the Drug Manufacturers industry, placing it in the top 94.9%.
Is Evotec SE's Gross Margin % too high?
Evotec SE's current Gross Margin % is -1.00%. Over the past 10 years, this metric has ranged from a low of 11.47 to a high of 35.59. Based on the distribution chart, Evotec SE ranks #890 out of 938 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #890 out of 938 companies for Gross Margin %. This places Evotec SE in the lower half of its industry. The industry median Gross Margin % is 48.44. Historically, Evotec SE's own Gross Margin % has ranged from 11.47 to 35.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Gross Margin % is -1.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $2.74 — trading 35.8% below its estimated fair value. The current Gross Margin % is -1.00%. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Evotec SE (EVO), the current Gross Margin % is -1.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVO) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $2.74 is trading 35.8% below its estimated GF Value™ of $4.27.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVO:
Gross Margin %: -1.00%
GF Value™: $4.27 vs. price of $2.74 (35.8% below fair value)
No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score
Get the complete analysis for EVO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVO has been successfully added to your 
